QR Code

Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication

1263W94 is a novel benzimidazole compound being developed for treatment of human cytomegalovirus infection. No adverse pharmacological effects were demonstrated in safety pharmacology studies with 1263W94. The minimal-effect dose in a 1-month rat study was 100 mg/kg/day, and the no-effect dose in a...

Full description

Saved in:
Published in:Antimicrob Agents Chemother
Main Authors: Koszalka, George W., Johnson, Nelson W., Good, Steven S., Boyd, Leslie, Chamberlain, Stanley C., Townsend, Leroy B., Drach, John C., Biron, Karen K.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology (ASM) 2002
Subjects:
Antiviral Agents
Online Access:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC127362/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12121907/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.46.8.2373-2380.2002
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items